Impax Laboratories (IPXL) and Amicus Therapeutics (FOLD) Head-To-Head Review
Impax Laboratories (NASDAQ: IPXL) and Amicus Therapeutics (NASDAQ:FOLD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Insider and Institutional Ownership
83.6% of Impax Laboratories shares are held by institutional investors. 3.3% of Impax Laboratories shares are held by insiders. Comparatively, 3.4% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Impax Laboratories and Amicus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Impax Laboratories and Amicus Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Impax Laboratories||$812.82 million||1.63||$144.42 million||($8.07)||-2.21|
|Amicus Therapeutics||$16.28 million||125.55||-$186.93 million||($1.47)||-8.45|
Impax Laboratories has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Impax Laboratories, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Impax Laboratories has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Impax Laboratories and Amicus Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Impax Laboratories presently has a consensus price target of $19.57, indicating a potential upside of 9.95%. Amicus Therapeutics has a consensus price target of $14.58, indicating a potential upside of 17.42%. Given Amicus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Impax Laboratories.
Amicus Therapeutics beats Impax Laboratories on 7 of the 13 factors compared between the two stocks.
About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
About Amicus Therapeutics
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.